Elite Pharmaceuticals Inc Financials
Financial Health Signals
Based on FY2025 annual data. Scores normalized against common benchmarks. How we calculate these scores
Elite Pharmaceuticals Inc has an operating margin of 23.3%, meaning the company retains $23 of operating profit per $100 of revenue. This strong profitability earns a score of 100/100, reflecting efficient cost management and pricing power. This is up from 19.1% the prior year.
Elite Pharmaceuticals Inc's revenue surged 48.4% year-over-year to $84.0M, reflecting rapid business expansion. This strong growth earns a score of 100/100.
Elite Pharmaceuticals Inc carries a low D/E ratio of 0.80, meaning only $0.80 of long-term debt for every $1 of shareholders' equity. This conservative leverage earns a score of 81/100, indicating a strong balance sheet with room for future borrowing.
With a current ratio of 4.88, Elite Pharmaceuticals Inc holds $4.88 in current assets for every $1 of short-term obligations. This comfortable liquidity earns a score of 100/100.
Elite Pharmaceuticals Inc has a free cash flow margin of 6.9%, earning a moderate score of 35/100. The company generates positive cash flow after capital investments, but with room for improvement.
Elite Pharmaceuticals Inc scores 10.70, well above the 2.99 safe threshold. The score is driven primarily by a large market capitalization ($739.0M) relative to total liabilities ($42.9M). This indicates low bankruptcy risk based on profitability, leverage, and asset efficiency.
Elite Pharmaceuticals Inc passes 5 of 9 financial strength tests. 2 of 4 profitability signals pass, 1 of 3 leverage/liquidity signals pass, both operating efficiency signals pass.
For every $1 of reported earnings, Elite Pharmaceuticals Inc generates $-1.73 in operating cash flow ($7.5M OCF vs -$4.3M net income). This mixed ratio suggests some earnings may rely on non-cash accounting items.
Elite Pharmaceuticals Inc earns $152.8 in operating income for every $1 of interest expense ($19.6M vs $128K). This wide margin provides strong safety for debt servicing, even if earnings decline temporarily.
This page shows Elite Pharmaceuticals Inc (ELTP) financial statements, including the income statement, balance sheet, cash flow statement, and key financial ratios. View 15 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).
Key Financial Metrics
Elite Pharmaceuticals Inc generated $84.0M in revenue in fiscal year 2025. This represents an increase of 48.4% from the prior year.
Elite Pharmaceuticals Inc's EBITDA was $20.8M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization. This represents an increase of 72.0% from the prior year.
Elite Pharmaceuticals Inc generated $5.8M in free cash flow in fiscal year 2025, representing cash available after capex. This represents an increase of 244.2% from the prior year.
Elite Pharmaceuticals Inc reported -$4.3M in net income in fiscal year 2025. This represents a decrease of 121.5% from the prior year.
Elite Pharmaceuticals Inc earned $0.00 per diluted share (EPS) in fiscal year 2025. This represents a decrease of 100.0% from the prior year.
Elite Pharmaceuticals Inc held $11.8M in cash against $0 in long-term debt as of fiscal year 2025.
Elite Pharmaceuticals Inc had 1.07B shares outstanding in fiscal year 2025. This represents an increase of 0.0% from the prior year.
Elite Pharmaceuticals Inc's gross margin was 47.7% in fiscal year 2025, indicating the percentage of revenue retained after direct costs. This is up 1.1 percentage points from the prior year.
Elite Pharmaceuticals Inc's operating margin was 23.3% in fiscal year 2025, reflecting core business profitability. This is up 4.3 percentage points from the prior year.
Elite Pharmaceuticals Inc's net profit margin was -5.1% in fiscal year 2025, showing the share of revenue converted to profit. This is down 40.6 percentage points from the prior year.
Elite Pharmaceuticals Inc invested $8.0M in research and development in fiscal year 2025. This represents an increase of 15.7% from the prior year.
Elite Pharmaceuticals Inc invested $1.6M in capex in fiscal year 2025, funding long-term assets and infrastructure. This represents an increase of 100.7% from the prior year.
ELTP Income Statement
| Metric | Q2'25 | Q1'25 | Q3'24 | Q2'24 | Q1'24 | Q3'23 | Q2'23 | Q1'23 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $36.3M-9.7% | $40.2M+179.9% | $14.4M-23.9% | $18.9M+0.4% | $18.8M+21.0% | $15.5M+9.8% | $14.2M+57.7% | $9.0M |
| Cost of Revenue | $22.2M+71.3% | $13.0M+57.5% | $8.2M-22.8% | $10.7M+3.4% | $10.3M+21.5% | $8.5M+10.2% | $7.7M+82.3% | $4.2M |
| Gross Profit | $14.1M-48.3% | $27.2M+344.9% | $6.1M-25.4% | $8.2M-3.3% | $8.5M+20.4% | $7.0M+9.2% | $6.4M+35.7% | $4.8M |
| R&D Expenses | $1.4M-17.3% | $1.7M-6.6% | $1.8M-8.8% | $2.0M-9.1% | $2.2M+54.1% | $1.4M-46.4% | $2.6M+129.0% | $1.1M |
| SG&A Expenses | $4.0M+18.4% | $3.4M+24.9% | $2.7M+19.8% | $2.3M+15.5% | $2.0M+15.1% | $1.7M+11.6% | $1.5M-7.7% | $1.7M |
| Operating Income | $8.2M-62.1% | $21.7M+1876.6% | $1.1M-68.5% | $3.5M-9.8% | $3.9M+9.4% | $3.5M+83.5% | $1.9M+20.2% | $1.6M |
| Interest Expense | $28K-1.9% | $29K-7.4% | $31K-6.2% | $33K-5.0% | $35K-71.3% | $122K-6.8% | $130K+9.2% | $119K |
| Income Tax | $2.0M-62.6% | $5.3M+2124.5% | $239K-84.2% | $1.5M+554.0% | $232K+129.0% | -$801K+95.5% | -$17.7M-11501.8% | $155K |
| Net Income | $13.7M+332.8% | -$5.9M+46.0% | -$10.9M+1.3% | -$11.0M-1892.3% | $616K-12.8% | $706K-95.3% | $14.9M+1208.0% | $1.1M |
| EPS (Diluted) | $0.01+200.0% | $-0.010.0% | $-0.010.0% | $-0.01 | $0.00 | $0.00-100.0% | $0.01 | $0.00 |
ELTP Balance Sheet
| Metric | Q2'25 | Q1'25 | Q3'24 | Q2'24 | Q1'24 | Q3'23 | Q2'23 | Q1'23 |
|---|---|---|---|---|---|---|---|---|
| Total Assets | $117.2M+5.3% | $111.3M+22.7% | $90.8M+2.9% | $88.2M+0.4% | $87.8M+17.6% | $74.7M+5.6% | $70.7M+52.1% | $46.5M |
| Current Assets | $85.8M+10.2% | $77.9M+62.0% | $48.0M+6.1% | $45.3M+4.9% | $43.2M+16.2% | $37.2M+7.0% | $34.7M+26.5% | $27.4M |
| Cash & Equivalents | $27.1M+22.0% | $22.2M+153.9% | $8.7M-12.6% | $10.0M+13.0% | $8.8M+52.1% | $5.8M-32.8% | $8.7M-4.7% | $9.1M |
| Inventory | $18.2M-6.2% | $19.4M-4.0% | $20.2M+42.3% | $14.2M+2.4% | $13.8M-3.4% | $14.3M-5.9% | $15.2M+36.3% | $11.2M |
| Accounts Receivable | $40.9M+12.8% | $36.2M+96.3% | $18.5M-13.9% | $21.4M+4.7% | $20.5M+28.0% | $16.0M+52.5% | $10.5M+69.2% | $6.2M |
| Goodwill | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Total Liabilities | $55.7M-12.6% | $63.7M+17.2% | $54.3M+32.7% | $40.9M+38.3% | $29.6M+4.6% | $28.3M+10.4% | $25.6M+56.4% | $16.4M |
| Current Liabilities | $10.7M-0.8% | $10.8M-26.7% | $14.7M+14.3% | $12.9M-8.3% | $14.0M-26.9% | $19.2M+0.4% | $19.1M+58.0% | $12.1M |
| Long-Term Debt | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Total Equity | $61.6M+29.2% | $47.7M+30.8% | $36.4M-22.9% | $47.3M-18.9% | $58.3M+25.5% | $46.4M+2.9% | $45.1M+49.7% | $30.1M |
| Retained Earnings | -$112.9M+10.8% | -$126.6M+8.1% | -$137.7M-8.6% | -$126.8M-9.5% | -$115.8M+3.3% | -$119.7M+0.6% | -$120.4M+11.0% | -$135.4M |
ELTP Cash Flow Statement
| Metric | Q2'25 | Q1'25 | Q3'24 | Q2'24 | Q1'24 | Q3'23 | Q2'23 | Q1'23 |
|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | $5.1M-65.5% | $14.8M+1489.1% | -$1.1M-173.0% | $1.5M-53.7% | $3.1M+231.6% | -$2.4M-912.5% | -$236K+91.3% | -$2.7M |
| Capital Expenditures | $103K-52.6% | $218K | $0-100.0% | $92K-88.1% | $779K | N/A | N/A | $536K |
| Free Cash Flow | $5.0M-65.6% | $14.6M+1468.6% | -$1.1M-178.0% | $1.4M-42.3% | $2.4M | N/A | N/A | $2.4M |
| Investing Cash Flow | -$103K+52.6% | -$218K | $0-100.0% | $18K+101.1% | -$1.7M | N/A | N/A | -$536K |
| Financing Cash Flow | -$116K+97.2% | -$4.1M-2039.1% | -$193K+39.8% | -$321K-83.3% | -$175K-365.5% | -$38K+79.1% | -$179K-104.5% | $4.0M |
| Dividends Paid | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Share Buybacks | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
ELTP Financial Ratios
| Metric | Q2'25 | Q1'25 | Q3'24 | Q2'24 | Q1'24 | Q3'23 | Q2'23 | Q1'23 |
|---|---|---|---|---|---|---|---|---|
| Gross Margin | 38.8%-29.0pp | 67.7%+25.1pp | 42.6%-0.8pp | 43.4%-1.7pp | 45.1%-0.2pp | 45.3%-0.2pp | 45.5%-7.4pp | 52.9% |
| Operating Margin | 22.6%-31.4pp | 54.0%+46.3pp | 7.6%-10.8pp | 18.5%-2.1pp | 20.5%-2.2pp | 22.7%+9.1pp | 13.6%-4.2pp | 17.8% |
| Net Margin | 37.7%+52.4pp | -14.6%+61.2pp | -75.8%-17.4pp | -58.5%-61.7pp | 3.3%-1.3pp | 4.5%-100.9pp | 105.5%+92.8pp | 12.7% |
| Return on Equity | 22.3% | N/A | N/A | N/A | 1.1%-0.5pp | 1.5%-31.6pp | 33.1%+29.3pp | 3.8% |
| Return on Assets | 11.7%+17.0pp | -5.3%+6.7pp | -12.0%+0.5pp | -12.5%-13.2pp | 0.7%-0.2pp | 0.9%-20.2pp | 21.1%+18.7pp | 2.5% |
| Current Ratio | 8.04+0.8 | 7.23+4.0 | 3.27-0.3 | 3.52+0.4 | 3.08+1.1 | 1.94+0.1 | 1.82-0.5 | 2.27 |
| Debt-to-Equity | 0.90-0.4 | 1.33-0.2 | 1.49+0.6 | 0.87+0.4 | 0.51-0.1 | 0.61+0.0 | 0.57+0.0 | 0.54 |
| FCF Margin | 13.8%-22.4pp | 36.2%+43.6pp | -7.4%-14.6pp | 7.2%-5.3pp | 12.6% | N/A | N/A | N/A |
Similar Companies
Frequently Asked Questions
What is Elite Pharmaceuticals Inc's annual revenue?
Elite Pharmaceuticals Inc (ELTP) reported $84.0M in total revenue for fiscal year 2025. This represents a 48.4% change compared to the previous fiscal year. Revenue measures the total income earned from the company's primary business operations before any expenses are deducted.
How fast is Elite Pharmaceuticals Inc's revenue growing?
Elite Pharmaceuticals Inc (ELTP) revenue grew by 48.4% year-over-year, from $56.6M to $84.0M in fiscal year 2025.
Is Elite Pharmaceuticals Inc profitable?
No, Elite Pharmaceuticals Inc (ELTP) reported a net income of -$4.3M in fiscal year 2025, with a net profit margin of -5.1%.
What is Elite Pharmaceuticals Inc's earnings per share (EPS)?
Elite Pharmaceuticals Inc (ELTP) reported diluted earnings per share of $0.00 for fiscal year 2025. This represents a -100.0% change compared to the previous fiscal year. EPS represents the portion of a company's net income allocated to each outstanding share of common stock and is widely used to evaluate profitability on a per-share basis.
What is Elite Pharmaceuticals Inc's EBITDA?
Elite Pharmaceuticals Inc (ELTP) had EBITDA of $20.8M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization.
What is Elite Pharmaceuticals Inc's gross margin?
Elite Pharmaceuticals Inc (ELTP) had a gross margin of 47.7% in fiscal year 2025, indicating the percentage of revenue retained after direct costs of goods sold.
What is Elite Pharmaceuticals Inc's operating margin?
Elite Pharmaceuticals Inc (ELTP) had an operating margin of 23.3% in fiscal year 2025, reflecting the profitability of core business operations before interest and taxes.
What is Elite Pharmaceuticals Inc's net profit margin?
Elite Pharmaceuticals Inc (ELTP) had a net profit margin of -5.1% in fiscal year 2025, representing the share of revenue converted into profit after all expenses.
What is Elite Pharmaceuticals Inc's free cash flow?
Elite Pharmaceuticals Inc (ELTP) generated $5.8M in free cash flow during fiscal year 2025. This represents a 244.2% change compared to the previous fiscal year. Free cash flow represents the cash a company generates after accounting for capital expenditures, and is widely used to assess financial flexibility and shareholder value.
What is Elite Pharmaceuticals Inc's operating cash flow?
Elite Pharmaceuticals Inc (ELTP) generated $7.5M in operating cash flow during fiscal year 2025, representing cash generated from core business activities.
What are Elite Pharmaceuticals Inc's total assets?
Elite Pharmaceuticals Inc (ELTP) had $96.4M in total assets as of fiscal year 2025, including both current and long-term assets.
What are Elite Pharmaceuticals Inc's capital expenditures?
Elite Pharmaceuticals Inc (ELTP) invested $1.6M in capital expenditures during fiscal year 2025, funding long-term assets and infrastructure.
How much does Elite Pharmaceuticals Inc spend on research and development?
Elite Pharmaceuticals Inc (ELTP) invested $8.0M in research and development during fiscal year 2025.
How many shares does Elite Pharmaceuticals Inc have outstanding?
Elite Pharmaceuticals Inc (ELTP) had 1.07B shares outstanding as of fiscal year 2025.
What is Elite Pharmaceuticals Inc's current ratio?
Elite Pharmaceuticals Inc (ELTP) had a current ratio of 4.88 as of fiscal year 2025, which is generally considered healthy.
What is Elite Pharmaceuticals Inc's debt-to-equity ratio?
Elite Pharmaceuticals Inc (ELTP) had a debt-to-equity ratio of 0.80 as of fiscal year 2025, measuring the company's financial leverage by comparing total debt to shareholder equity.
What is Elite Pharmaceuticals Inc's return on assets (ROA)?
Elite Pharmaceuticals Inc (ELTP) had a return on assets of -4.5% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.
What is Elite Pharmaceuticals Inc's Altman Z-Score?
Elite Pharmaceuticals Inc (ELTP) has an Altman Z-Score of 10.70, placing it in the Safe Zone (low bankruptcy risk). The Z-Score combines five financial ratios—working capital, retained earnings, EBIT, market capitalization, and revenue relative to total assets—to predict the likelihood of bankruptcy. Scores above 2.99 indicate financial safety while scores below 1.81 suggest financial distress. Learn more in our complete guide to financial health indicators.
What is Elite Pharmaceuticals Inc's Piotroski F-Score?
Elite Pharmaceuticals Inc (ELTP) has a Piotroski F-Score of 5 out of 9, indicating neutral financial health. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7–9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.
Are Elite Pharmaceuticals Inc's earnings high quality?
Elite Pharmaceuticals Inc (ELTP) has an earnings quality ratio of -1.73x, considered mixed quality. This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.
Can Elite Pharmaceuticals Inc cover its interest payments?
Elite Pharmaceuticals Inc (ELTP) has an interest coverage ratio of 152.8x, meaning it can comfortably cover its interest obligations. This ratio divides operating income by interest expense. Ratios above 5x indicate strong debt-servicing ability, while ratios below 2x suggest the company may face difficulty meeting interest payments if earnings decline. Learn more in our complete guide to financial health indicators.
How financially healthy is Elite Pharmaceuticals Inc?
Elite Pharmaceuticals Inc (ELTP) scores 83 out of 100 on our Financial Profile, indicating strong overall financial health. This composite score evaluates six dimensions: profitability (operating margin), revenue growth, leverage (debt-to-equity), liquidity (current ratio), cash flow quality (free cash flow margin), and shareholder returns (return on equity). Each dimension is normalized against standard financial benchmarks. Learn more in our complete guide to financial health indicators.